Epigenetic changes in pediatric neuroblastoma may contribute to the aggressive pathophysiology of this disease, but little is known about the basis for such changes. In this study, we examined a role for the DNA methyltransferase DNMT3B, in particular, the truncated isoform DNMT3B7 which is generated frequently in cancer. To investigate if aberrant DNMT3B transcripts alter DNA methylation, gene expression, and phenotypic character in neuroblastoma, we measured DNMT3B expression in primary tumors.
Introduction
In adult cancers, epigenetic changes and aberrant splicing of DNMT3B are observed frequently (1, 2) . Pediatric neuroblastoma is characterized by a range of clinical behaviors, and genetic and epigenetic aberrations contribute to pathogenesis (3) (4) (5) . The Cohn laboratory and others have shown that hypermethylation and silencing of genes involved in the regulation of tumor growth, cell cycle, apoptosis, and DNA repair are associated with aggressive growth and poor outcome in patients (6) (7) (8) . Further, poor prognosis can be predicted by a CpG island methylator phenotype (9) . Preclinical studies have demonstrated that neuroblastoma growth can be inhibited by drugs that disrupt DNA methylation (10, 11) . Retinoic acid, a differentiation-inducing agent that has been shown to improve clinical outcome (12) , can reverse the methylation status of hundreds of gene promoters (13) , possibly due to decreased levels of the DNA methyltransferase enzymes (14) .
Three DNA methyltransferase (DNMT) enzymes regulate DNA methylation in eukaryotic cells (15) (16) (17) , with widespread aberrant DNMT3B transcription in cancer cells encoding truncated proteins lacking the catalytic domain (1, 2, (18) (19) (20) . Forced expression of DNMT3B7 within 293 cells led to altered DNA methylation levels and corresponding gene expression changes, indicating that DNMT3B7 expression could alter DNA methylation levels and gene expression (18) . DNMT3B7 transgenic mice exhibit altered embryonic development (21).
Despite advances in genome-wide profiling that demonstrate strong correlations between genetic aberrations and clinical phenotype, we know much less about the clinical significance of epigenetic changes in neuroblastoma. Given that aberrant DNMT3B isoforms are common in cancer cells, we hypothesized that aberrant DNMT3B transcripts found in neuroblastoma tumors could alter DNA methylation, gene expression, and tumor phenotype.
Materials and Methods
Patients and tumor specimens. Two ganglioneuroblastoma, three ganglioneuroma, and thirteen primary neuroblastoma tumors were obtained from Children's Memorial Hospital in Chicago under an IRB approved protocol. Twelve RNA samples derived from one ganglioneuroblastoma and eleven neuroblastomas were obtained from the Children's Oncology Group (COG) Neuroblastoma Tumor Bank. The laboratory studies were approved by The University of Chicago Institutional Review Board.
Cell culture, cell identification, and nucleic acid isolation. Cell line identities were verified by short tandem repeat profiling using the AmpF/STR Identifiler PCR Amplification Kit (Applied Biosystems, Carlsbad, CA). RNA and DNA isolation was performed using TRIzol (Invitrogen) and Puregene Core kit (Qiagen, Valencia, CA), respectively. ,
The MSCV-I-GFP plasmid backbone was engineered to confer constitutive DNMT3B7 expression using a 5′ EcoRI site, C-terminal His-tag epitope, and 3′ XhoI site using primers listed in Supplementary Table S1 . Retroviral constructs and packaging plasmid psi-Eco were used to produce retroviral supernatants by 293T cell cotransfection using Fugene6 Transfection Reagent (Roche, Indianapolis, IN).
The inducible DNMT3B7 construct was generated using oligonucleotides listed in Supplementary Table S1 to ligate into the pRetroX-Tight-Pur response vector (pRXTPL) (Clontech Laboratories, Palo Alto, CA). The Tet-Off System (Clontech) was used to produce inducible LA1-55n cell lines. In the presence of doxycycline, there is no induction of gene expression in either the control or DNMT3B7-containing cell line. In the absence of doxycycline, the DNMT3B7-containing cells express both GFP and DNMT3B7, and the vector control cells express only GFP. We have compared the vector cells expressing GFP to the experimental cells expressing GFP and DNMT3B7 to control for any effects of GFP expression.
All plasmid inserts were sequenced to ensure proper correct sequence.
Neuroblastoma xenograft studies. Four-to six-week-old female homozygous athymic nude mice (Harlan, Madison, WI) were inoculated subcutaneously into the right flank with DNMT3B7-expressing cells (or control) and measured twice weekly (see Supplementary Material and Methods for details). Tumor volumes were measured twice weekly and calculated using the following formula: tumor volume = (length x width 2 ) / 2. Mice bearing SMS-KCNR (constitutive expression) xenografts were sacrificed after 28 days. Mice bearing LA1-55n (inducible expression) xenografts were divided randomly into two groups when palpable tumors developed; control mice continued receiving doxycyclinecontaining water to block DNMT3B7 expression, and animals in the experimental group were given normal drinking water to induce DNMT3B7 expression. Mice in both groups were sacrificed after 35 days.
Immunohistochemical analysis. Immunohistochemistry was performed for CD-31
(1:100, M-20, Santa Cruz Biotechnology) to determine the mean vascular density, and Ki-67 (1:200, MIB-1, DakoCytomation) to assess proliferation rate (10) .
Quantification of apoptosis.
In situ detection of apoptosis was performed using the In Situ Cell Death Detection kit (Roche Diagnostics Corp., Indianapolis, IN) (22) .
Liquid chromatography-mass spectroscopy (LC/MS). Total cytosine methylation was
performed by LC/MS, as described previously (21). Sodium bisulfite treatment, PCR amplification, and protein expression analysis.
Genomic DNA was treated with sodium bisulfite (23) , and PCR amplifications were performed using the primers listed in Supplementary Table S1 using ZymoTaq (ZymoResearch) at the indicated temperatures. Reverse transcription was performed using Superscript III (Invitrogen), and PCR amplifications were performed using Platinum Taq (Invitrogen) using primers listed in Supplementary Table S1 . Whole cell extracts were made by lysing cells in 75mM NaCl, 25mM Tris-Cl, and 1:100 protease inhibitors (CalBiochem). DNMT3B was detected with T-16 antibody (1:500, sc-10236, Santa Cruz Biotechnology), and TOP1 was used as a loading control (1:400 dilution ab3825
AbCam).
RNA-Sequencing (RNA-Seq).
Total RNAs were isolated using Trizol Reagent (Invitrogen). RNA integrity was validated using the Agilent BioAnalyzer, and all samples had an RNA integrity number >9. Libraries were generated following the Illumina protocol for Preparing Samples for Sequencing of mRNA. PCR amplified cDNA libraries were quantified on an Agilent 2100 Bioanalyzer. Single-end sequencing was performed for 36-cycles using Single Read Cluster Generation Kit V4 (Cat# GD-103-4001) and Sequencing Kits (Cat# FC-104-4002). Sequence reads from the RNA-sequencing were aligned to genomic sequence (Human Feb. 2009 assembly, GRCh37/hg19). RNASequencing data have been submitted to the GEO database, record number GSE36350.
Statistical analyses. Statistical analysis was performed using a two-tailed Student's t test or Fisher' Exact Test. A P-value ≤ 0.05 was considered statistically significant. For the RNA Sequencing data, each DNMT3B7-expressing cell line was compared to the vector control and Bonferroni correction was used to correct for multiple testing using n=18,674, the total number of genes that had at least one read in all three cell lines. 
Results

Aberrant DNMT3B transcripts are expressed in primary neuroblastoma tumors
To investigate significance of aberrant DNMT3B transcripts in neuroblastoma, reverse transcriptase-PCR (RT-PCR) analysis was performed on a hypothesisgenerating cohort of three ganglioneuroblastoma, three ganglioneuromas, and 24 primary neuroblastoma samples using primers that amplified all but two of the known alternative and aberrant DNMT3B isoforms (Fig. 1A, Supplementary Fig. S1A , Table 1 ).
Additional DNMT3B transcripts were detected by Southern Blot using a DNMT3B probe that hybridizes to all of the known aberrant isoforms amplified in the RT-PCR ( Supplementary Fig. S1B, C) . We stratified the patients into two risk groups: high risk and non-high risk. Non-high risk patients included those with stages 1 and 2 disease, infants with stages 4 and 4S tumors, and patients with stage 3 tumors that lacked MYCN amplification. Similar to the criteria used by the COG, patients with stage 3 MYCNamplified tumors and children older than 1 year of age with stage 4 disease were considered high risk (4) . We found the expression of four or more aberrant DNMT3B isoforms correlated with higher risk groups (P=0.03). The identity of DNMT3B7 was confirmed by sequencing in four primary tumors (data not shown), and expression of DNMT3B7 was quantified in the primary tumors by real-time RT-PCR ( Supplementary   Fig. S2A ). We obtained ten more ganglioneuroblastoma RNAs from the COG. However, the integrity of the RNA was too low to determine the levels of DNMT3B isoforms (data not shown). We therefore hypothesized that high levels of DNMT3B7 may contribute to the more benign clinical behavior of the most differentiated tumors.
Neuroblastoma cell lines showed expression patterns of DNMT3B transcripts similar to that of the primary tumors by RT-PCR (Fig. 1B) . Tumorigenic N-type cells (24) had an increased number of DNMT3B transcripts and lacked DNMT3B7. By Western blot, we found the N-type cells have only full-length DNMT3B, whereas non-tumorigenic S-type cells had both full-length DNMT3B and the truncated DNMT3B7 (Fig. 1C ).
Forced expression of DNMT3B7 in neuroblastoma cells inhibits growth
Because we detected high levels of DNMT3B7 in differentiated tumors associated with more favorable outcomes, we hypothesized that DNMT3B7 could modify neuroblastoma phenotype. We introduced DNMT3B7 into an N-type neuroblastoma cell line (LA1-55n) using a Tet-off inducible system. Repression of cell growth in the DNMT3B7-expressing cell lines was seen after ten days of induction (P<0.001) ( S3 ).
Both the inducible DNMT3B7-LA1-55n cells and constitutively-expressing
DNMT3B7-SMS-KCNR cells were used to test the effects of DNMT3B7 expression on
tumor growth in murine xenograft models using LA1-55n cells (Fig. 3A) and SMS-KCNR cells (Fig. 3C) . In both models, expression of DNMT3B7 inhibited tumor growth (Fig. 3A, C). Tumor vascularity, cell proliferation, and apoptosis were evaluated in both the LA1-55n ( Fig. 3B ) and SMS-KCNR ( 
DNMT3B7 expression cells have higher levels of global DNA methylation
We have shown previously that DNMT3B7 expression in an Eμ-Myc transgenic mouse model resulted in an increase in global DNA methylation (21). To determine if the expression of DNMT3B7 in the LA1-55n cells also increases DNA methylation, we measured global DNA methylation levels. As shown in Figure 4A , significantly higher levels of DNA methylation were detected in the LA1-55n expressing DNMT3B7 as compared to vector control cells. We found the methylation of Satellite 2 repetitive elements to have more DNA methylation following DNMT3B7-expression in the LA1-55n cells ( Supplementary Fig S5) . The increase in DNA methylation was also seen in both DNMT3B7-expressing xenografts. A statistically significant increase in total 5-methylcytosine levels was seen in the DNMT3B7-expressing tumors compared to Fig. 4B ), indicating that the pattern of DNA methylation is modified in the presence of the truncated DNMT3B7. Because we identified high levels of DNMT3B7 in ganglioneuroblastomas, we hypothesized that this would correlate with global DNA methylation levels. We found no difference between low, intermediate, and high risk groups. However, there was a statistically significant increase in global DNA methylation in the three ganglioneuroblastoma tumors (28, 65-1 and 2235) two of which have the highest level of DNMT3B7 expression seen in any primary tumor (Fig. 4C ).
DNMT3B7 expression induces changes in gene expression and DNA methylation
To investigate the effects of DNMT3B7 on gene expression, we used RNASequencing to compare the gene expression profiles of two independent DNMT3B7-expressing LA1-55n cells to vector control cells after 21 days of induction. After eliminating the genes with fewer than 150 reads per cell and those that had less than a three-fold change in either of the two DNMT3B7-expressing cell lines compared to the vector control, there were 144 genes that had at least an average five-fold change in the two DNMT3B7-expressing cell lines compared to the vector control cells (Supplementary   Table S2 (Fig. 5A, B) .
To test if the differential expression of genes in the DNMT3B7-expressing LA1-55n cells was the result of an alteration in their DNA methylation patterns, we performed bisulfite sequencing of eight genes that had been validated by real-time RT-PCR. Six of these genes showed no detectable DNA methylation across the transcriptional start site.
RXRB, a gene important in retinoic acid signaling, showed a decrease expression of two-fold in DNMT3B7-expressing cells by real-time RT-PCR, and the CpG island surrounding the transcriptional start site was hypermethylated in the presence of DNMT3B7 (Fig. 5C) . Similarly, EEA1 expression was nine-fold higher by real-time RT- 
PCR, and the CpG island upstream of the transcriptional start site became completely hypomethylated in DNMT3B7-expressing cells (Fig. 5D) . The changes in DNA methylation were validated by LC/MS (Supplementary Fig. S8 ). These data show that expression of DNMT3B7 in neuroblastoma cells leads changes in gene expression, some of which are correlated to altered CpG island methylation.
The effects of ATRA and DNMT3B7 expression on growth inhibition are additive RNA-Sequencing of the DNMT3B7-expressing LA1-55n cells revealed decreased expression of genes encoding components of the AP1 complex, FOSB (45-fold), FOS (11-fold), and JUNB (six-fold). In addition to acting as a transcription factor, AP1 can also antagonize the activity of retinoic acid receptors (27) . We therefore hypothesized that, with reduced levels of AP1, retinoic acid receptors would be more active and could drive DNMT3B7-expressing cells toward differentiation. To test if retinoic acid treatment could augment the ability of DNMT3B7 to induce differentiation of neuroblastoma cells, we induced DNMT3B7 expression in the LA1-55n cells for two weeks to maximize DNMT3B7 expression (Fig. 2B) . After two weeks of induction, both DNMT3B7-expressing cells and control cells were treated either with all-trans retinoic acid (ATRA) or vehicle for seven days. We found that the effects of ATRA treatment and DNMT3B7 expression on growth inhibition were additive (Fig. 6A) , not synergistic.
To test if DNMT3B7-expressing cells were more differentiated than control cells, we studied the expression of 22 known neuroblastoma differentiation markers (28) (29) (30) (31) (32) (33) and found that 18 of them had expression changes that correlated with a more differentiated phenotype (Supplementary Table S3 ). We validated the two genes with the greatest fold changes: GFRA1 and DLK1. GFRA1 encodes GDNF family receptor alpha 1 and has been shown to enhance differentiation in response to GDNF (34) . GFRA1 expression was two-fold higher in two independent DNMT3B7-expressing LA1-55n cell lines, compared to vector control (Fig. 6B left, dark gray bars) . After ATRA treatment, GFRA1 expression was further increased in all cell lines (Fig. 6B left, light gray bars), and this increase was greater in the DNMT3B7-expressing cells. DLK1 encodes deltalike 1 homolog (Drosophila) and has been identified as a stem cell gene that negatively regulates differentiation (35) . The expression of DLK1 in DNMT3B7-expressing cells was decreased up to two-fold in two independent DNMT3B7-expressing LA1-55n cell lines (Fig. 6B right, dark gray bars) . After ATRA treatment, DLK1 expression was further decreased in all cell lines (Fig. 6B left, light gray bars) , and the expression in the Many of the encoded proteins lack either the DNA binding or catalytic domains, and some have been shown to modify the pattern of DNA methylation and gene expression (18, 20) . In this study, we found DNMT3B7 transcripts in all of the ganglioneuromas tested and at very high levels in all of the ganglioneuroblastomas, leading us to the hypothesis that DNMT3B7 could induce differentiation and lead to a more benign phenotype, thereby modifying tumor phenotype in pediatric neuroblastoma.
To test this hypothesis, we forced DNMT3B7 expression in neuroblastoma cells using retroviral vectors to drive either constitutive or inducible expression and evaluated its effects on DNA methylation, tumor growth, and angiogenesis. We observed growth has been found to correlate with high-risk neuroblastoma tumors (40) . ROCK1 (six-fold) and ROCK2 (six-fold) were both under-expressed in DNMT3B7-expressing cells, and activated RhoA and its downstream effector ROCK have been shown to be negative regulators of growth cone motility (41) . Adenomatous polyposis coli (APC) is a tumor suppressor gene, highly expressed in the developing and adult nervous system, which is involved in neurite formation (42, 43) , and apoptosis of neural crest cells (44) .
Additionally, GeneGo pathway analysis of the RNA-Sequencing data revealed decreased expression of genes encoding the components of the AP1 complex, which can antagonize the activity of retinoic acid receptors through protein-protein interaction without requiring DNA binding (27) . We therefore hypothesized that, with reduced levels of AP1, retinoic acid receptors would be more active in the DNMT3B7-expressing cells, allowing augmentation of differentiation by retinoid treatment. Indicative of increased differentiation, DNMT3B7-expressing LA1-55n cells had higher expression of GFRA1 compared to vector controls following ATRA treatment. Similarly, the expression of DLK1 was decreased in both DNMT3B7-expressing LA1-55n cell lines following ATRA treatment (Fig. 6B) . It has been shown previously that ATRA treatment of another MYCN amplified neuroblastoma cell line (SK-N-BE) leads to promoter hypomethylation (14), although we did not observe any significant global changes in DNA methylation after ATRA treatment (Supplementary Fig. S9 ). In the future, screening neuroblastoma tumors for DNMT3B7-expression may indicate particular patients for whom ATRA 
treatment might be particularly effective. DNMT3B exists in a protein complex with the mitotic chromatin condensation components, including HDAC1 and SIN3A (45) . When unbound, retinoic acid receptors (RARs) bind NCOR2, SIN3A, and HDACs, leading to target promoter repression, which can be disassociated upon ATRA binding (46, 47) . (49) . Retinoic acid treatment therefore, leads to a reduction in repressive histone marks in addition to the changes in DNA methylation described above. Therefore, future work may focus on testing whether histone modifications are altered in this system. Our findings suggest that forced expression of DNMT3B7 in neuroblastoma cells is able to drive genome-wide DNA methylation. This is similar to the effects seen in lymphomas that arise in Eμ-Myc/DNMT3B7 transgenic mice (21). However, in neuroblastoma, the expression of DNMT3B7 is anti-tumorigenic (Fig. 3) , whereas 
distribution of DNA methylation seen in virtually all human cancers. We hope that our discoveries will also provide a basis for novel diagnostic, prognostic, and therapeutic strategies that will be applicable to neuroblastoma and other types of tumors. 
